Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbbVie's Ending Cash Position for the quarter that ended in Mar. 2026 was MXN169,345 Mil.
AbbVie's quarterly Ending Cash Position
declined
from Sep. 2025 (MXN103,260 Mil) to Dec. 2025 (MXN94,152 Mil) but then
increased
from Dec. 2025 (MXN94,152 Mil) to Mar. 2026 (MXN169,345 Mil).
AbbVie's annual Ending Cash Position
declined
from Dec. 2023 (MXN217,508 Mil) to Dec. 2024 (MXN115,207 Mil) and
declined
from Dec. 2024 (MXN115,207 Mil) to Dec. 2025 (MXN94,152 Mil).
AbbVie Ending Cash Position Related Terms
AbbVie Ending Cash Position Historical Data
* Premium members only.
The historical data trend for AbbVie's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
AbbVie's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN169,345 Mil mean?
AbbVie (MEX:ABBV) has a Ending Cash Position of MXN169,345 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on AbbVie and its competitors.
Is AbbVie's Ending Cash Position too high?
AbbVie's current Ending Cash Position is MXN169,345 Mil. Overall, AbbVie has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Ending Cash Position compare to MRK and JNJ?
AbbVie's Ending Cash Position of MXN169,345 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on AbbVie and its competitors. AbbVie's current Ending Cash Position is MXN169,345 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,732.43, compared to a current price of MXN4,608.00 — trading 23.5% above its estimated fair value. The current Ending Cash Position is MXN169,345 Mil. AbbVie's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Ending Cash Position is MXN169,345 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (MEX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of MXN4,608.00 is trading 23.5% above its estimated GF Value™ of MXN3,732.43.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for MEX:ABBV:
Ending Cash Position: MXN169,345 Mil
GF Value™: MXN3,732.43 vs. price of MXN4,608.00 (23.5% above fair value)
No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
67GF Score
Get the complete analysis for MEX:ABBV
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ABBV has been successfully added to your 
